All Studies Meta Analysis

The Effects of 10,000 IU Vitamin D Supplementation on Improvement of Clinical Outcomes, Inflammatory and Coagulation Markers in Moderate COVID-19 Patients: A Randomized-Controlled Trial

Taslim et al., Nutr. clín. diet. hosp., doi:10.12873/432taslim, NCT05126602

May 2023

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

Vitamin D for COVID-19

8th treatment shown to reduce risk in October 2020, now with p < 0.00000000001 from 122 studies, recognized in 9 countries.

Lower risk for mortality, ICU admission, hospitalization, progression, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,000+ studies for 109 treatments. c19early.org

RCT 72 moderate COVID-19 patients with vitamin D deficiency or insufficiency in Indonesia, showing faster viral clearance and improved recovery with 10,000IU vitamin D vs. 1,000IU vitamin D. Higher vitamin D levels were associated with shorter length of stay (p = 0.009).

10,000IU vs. 1,000IU cholecalciferol daily for 2 weeks.

Cholecalciferol was used in this study. Meta analysis shows that late stage treatment with calcitriol / calcifediol (or paricalcitol, alfacalcidol, etc.) is more effective than cholecalciferol: 69% [47‑82%] lower risk vs. 39% [27‑49%] lower risk. Cholecalciferol requires two hydroxylation steps to become activated - first in the liver to calcifediol, then in the kidney to calcitriol. Calcitriol, paricalcitol, and alfacalcidol are active vitamin D analogs that do not require conversion. This allows them to have more rapid onset of action compared to cholecalciferol. The time delay for cholecalciferol to increase serum calcifediol levels can be 2-3 days, and the delay for converting calcifediol to active calcitriol can be up to 7 days.

Important missing comments or errors? Let us know.

risk of oxygen therapy, 71.4% lower, RR 0.29, p = 0.01, treatment 4 of 30 (13.3%), control 14 of 30 (46.7%), NNT 3.0.

risk of oxygen therapy, 66.7% lower, RR 0.33, p = 0.61, treatment 1 of 30 (3.3%), control 3 of 30 (10.0%), NNT 15, mask.

risk of oxygen therapy, 72.7% lower, RR 0.27, p = 0.03, treatment 3 of 30 (10.0%), control 11 of 30 (36.7%), NNT 3.8, nasal cannula.

risk of no recovery, 60.0% lower, RR 0.40, p = 0.42, treatment 2 of 30 (6.7%), control 5 of 30 (16.7%), NNT 10.0, fever.

hospitalization time, 21.0% lower, relative time 0.79, p < 0.001, treatment mean 11.63 (±2.5) n=30, control mean 14.73 (±3.45) n=30.

time to viral-, 37.6% lower, relative time 0.62, p < 0.001, treatment mean 6.53 (±1.17) n=30, control mean 10.47 (±2.56) n=30, primary outcome.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Taslim et al., 1 May 2023, Single Blind Randomized Controlled Trial, Indonesia, peer-reviewed, 10 authors, study period 1 April, 2021 - 30 September, 2021, trial NCT05126602 (history). Contact: pudji_taslim@yahoo.com.

This Paper Vitamin D All

The Effects of 10,000 IU Vitamin D Supplementation on Improvement of Clinical Outcomes, Inflammatory and Coagulation Markers in Moderate COVID-19 Patients: A Randomized-Controlled Trial

Nurpudji Astuti Taslim, Zahratul Fajri, Sisca Agustia Olii, Mardiana Madjid, Yasmin Syauki, Irawaty Djaharuddin, Agussalim Bukhari, Suryani As'ad, Haerani Rasyid, Nurpudji Astuti Taslim

doi:10.12873/432taslim

Background & aims: Vitamin D supplementation as an immunomodulator has been identified as a potential strategy to prevent and treat Coronavirus disease 2019 (COVID-19). We aimed to analyze the effect of 10,000 IU vitamin D3 supplementation on 25(OH)D levels on primary clinical outcomes (conversion length), inflammatory markers (Total Lymphocyte Count (TLC), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR)) and coagulation marker (D-Dimer

CONCLUSION The effects of 10,000 IU Vitamin D3 supplementation in moderate COVID-19 patients whom have low vitamin D status showed improvements in LOC, LOS, clinical manifestations, functional capacity, and positive correlation on inflammatory and coagulation markers, such as PLR.

References

Altaş, Tosun, Assessment of Vitamin D and inflammatory response relationship using neutrophil to lymphocyte ratio, platelet to lymphocyte ratio and mean platelet volume, Turk Osteoporoz Derg, doi:10.4274/tod.07108

Bennasrallah, Zemni, Dhouib, Factors associated with a prolonged negative conversion of viral RNA in patients with COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2021.02.089

Fiorindi, Campani, Rasero, Prevalence of nutritional risk and malnutrition during and after hospitalization for COVID-19 infection: Preliminary results of a single-centre experience, Clin Nutr ESPEN, doi:10.1016/j.clnesp.2021.07.020

Frassinette, Albuquerque, Xavier, Desfecho clínico e fatores associados em pacientes com COVID-19 internados em uma Unidade de Terapia Intensiva Clinical outcome and associated factors in patients with COVID-19 admitted to an Intensive Care Unit, doi:10.12873/424oliveira

Gotelli, Paolino, Soldano, Cutolo, Vitamin D Immune-Mediated Responses and SARS-CoV-2 Infection: Clinical Implications in COVID-19, Immuno, doi:10.3390/immuno2010001

Guan, Ni, Hu, Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, doi:10.1056/nejmoa2002032

Indonesia, Pedoman Tatalaksana COVID-19

King, The Role of Vitamin D deficiency in COVID-19 related deaths in BAME, Obese and Other High-risk Categories, doi:10.31232/osf.io/73whx

Kollias, Kyriakoulis, Dimakakos, Poulakou, Stergiou et al., Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action, Br J Haematol, doi:10.1111/bjh.16727

Lechien, Chiesa-Estomba, Place, Clinical and epidemiological characteristics of 1420 European patients with mildto-moderate coronavirus disease 2019, J Intern Med, doi:10.1111/joim.13089

Li, Zhou, Ba, Nutritional risk and therapy for severe and critical COVID-19 patients: A multicenter retrospective observational study, Clin Nutr, doi:10.1016/j.clnu.2020.09.040

Liu, Zhang, Wu, Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study, Ann Intensive Care, doi:10.1186/s13613-020-00706-3

Ludwig, Jacob, Basedow, Andersohn, Walker, Clinical outcomes and characteristics of patients hospitalized for Influenza or COVID-19 in Germany, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.204

Merzon, Tworowski, Gorohovski, Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study, FEBS J, doi:10.1111/febs.15495

Moriconi, Masi, Rebelos, Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding, Obes Res Clin Pract, doi:10.1016/j.orcp.2020.05.009

Murai, Fernandes, Sales, Effect of a Single High Dose of Vitamin D3on Hospital Length of Stay in Patients with Moderate to Severe COVID-19: A Randomized Clinical Trial, JAMA -J Am Med Assoc, doi:10.1001/jama.2020.26848

Musselwhite, Andrade, Ellenberg, Vitamin D, Ddimer, Interferon γ, and sCD14 Levels are Independently Associated with Immune Reconstitution Inflammatory Syndrome: A Prospective, International Study, EBioMedicine, doi:10.1016/j.ebiom.2016.01.016

Nicolau, Ayala, Sanchís, Influence of nutritional status on clinical outcomes among hospitalized patients with COVID-19, Clin Nutr ESPEN, doi:10.1016/j.clnesp.2021.04.013

Orchard, Baldry, Nasim-Mohi, Vitamin-D levels and intensive care unit outcomes of a cohort of critically ill COVID-19 patients, Clin Chem Lab Med, doi:10.1515/cclm-2020-1567

Pdgki, Panduan Praktis Penatalaksanaan Nutrisi COVID-19. Perhimpun Dr Spes Gizi Klin Indones

Pereira, Damascena, Azevedo, De Almeida Oliveira, Da et al., Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis, Crit Rev Food Sci Nutr, doi:10.1080/10408398.2020.1841090

Rastogi, Bhansali, Khare, Short term, high-dose vitamin D supplementation for COVID-19 disease: A randomised, placebocontrolled, study (SHADE study), Postgrad Med J. Published online, doi:10.1136/postgradmedj-2020-139065

Roth, Emmons-Bell, Alger, Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic, JAMA Netw Open, doi:10.1001/jamanetworkopen.2021.8828

Sabico, Enani, Sheshah, Effects of a 2-week 5000 iu versus 1000 iu vitamin d3 supplementation on recovery of symptoms in patients with mild to moderate covid-19: A randomized clinical trial, Nutrients, doi:10.3390/nu13072170

Sepandi, Taghdir, Alimohamadi, Afrashteh, Hosamirudsari H. Factors associated with mortality in COVID-19 patients: A systematic review and meta-analysis, Iran J Public Health, doi:10.18502/ijph.v49i7.3574

Shareef, Zwain, Mahbuba, Superiority of lymphocyte ratio over total leukocyte count in detecting the severity of COVID-19 pneumonia, Heliyon, doi:10.1016/j.heliyon.2021.e08412

Song, Chen, Yuan, Wang, Wang, Total lymphocyte count, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio as prognostic factors in advanced non-small cell lung cancer with chemoradiotherapy, Cancer Manag Res, doi:10.2147/CMAR.S188578

Spagnolo, Manson, Joffe, Sex and Gender Differences in Health: What the COVID-19 Pandemic Can Teach Us, Ann Intern Med, doi:10.7326/M20-1941

Wang, Wang, Gu, Vitamin D is related to handgrip strength in adult men aged 50 years and over: A population study from the TCLSIH cohort study, Clin Endocrinol (Oxf), doi:10.1111/cen.13952

Wu, Chen, Chan, The outbreak of COVID-19: An overview, J Chinese Med Assoc, doi:10.1097/JCMA.0000000000000270

Yang, Liu, Tao W Qiang, Li, Ming, The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients, Int Immunopharmacol, doi:10.1016/j.intimp.2020.106504

Yue, Li, Wang, Nutritional Support and Clinical Outcome of Severe and Critical Patients With COVID-19 Pneumonia, Front Nutr, doi:10.3389/fnut.2020.581679

Zhao, Meng, Kumar, Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis, Int J Infect Dis, doi:10.1016/j.ijid.2020.04.086

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0